Short answer
NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 7.01 (Regulation FD Disclosure). CMS revoked NVCR's Medicare billing privileges retroactive to Dec 17, 2025: cited as administrative re-validation process issue, not substantive disqualification.
NovoCure Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- CMS revoked NVCR's Medicare billing privileges retroactive to Dec 17, 2025: cited as administrative re-validation process issue, not substantive disqualification
- Revocation fully rescinded Feb 24, 2026; billing privileges reinstated retroactively to Dec 17, 2025: gap effectively closed
- Company continued treating existing and new patients throughout the ineligibility period
- NVCR believes zero revenue impact from the temporary revocation period
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NovoCure Ltd 8-K filings
Get the next NVCR 8-K as it lands
Follow NVCR for push alerts, or ask the research agent what this filing means.